Oxidized thymosin β4
AssigneesThe University Court of the University of Glasgow, Imperial Cancer Research Technology, Ltd., Robert Duncan Stevenson
InventorsRobert Duncan Stevenson, Anthony John Lawrence, John Young, Darryl John Cecil Pappin
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of oxidized thymosin β4 in therapy, more particularly in the treatment of diseases or conditions associated with an inflammatory response of septic shock.
Claims4
A method of treating an inflammatory condition in a subject comprising administering an oxidised thymosin β4, physiologically active variant, or salt thereof.
A method of treating sepsis in a subject comprising administering a therapeutic amount of an oxidised thymosin β4, physiologically active variant, or salt therof.
Dependencies are inferred from the claim text.